GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc. | 2025-10-16 22:22:03 | 73.34 | -0.04 | -0.05 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GEHC | 0001932393 | GE HealthCare Technologies Inc. | US36266G1076 | 549300OI9J7XOWZMUN85 | 882515116 | Nasdaq | 3844 | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | 1231 | DE | 500 WEST MONROE STREET | CHICAGO | IL | 60661 | UNITED STATES | US | 833-735-1139 | 500 WEST MONROE STREET, CHICAGO, IL, 60661 | 500 WEST MONROE STREET, CHICAGO, IL, 60661 | GE Healthcare Holding LLC | Healthcare | 1994-09-28 | Peter Arduini | 53,000 | https://www.gehealthcare.com/ | 33,000,000,000 | 458,275,427 | 456,562,037 | GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals. | 2025-10-10 19:21:39 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 33,000,000,000 | 1,000,000,000 | 3.125 | 457,298,310 | 1,941,081 | 0.4263 |
| 2023 | 32,000,000,000 | 32,000,000,000 | 100 | 455,357,229 | 1,431,090 | 0.3153 |
| 2022 | 0 | 0 | 100 | 453,926,139 | 453,926,139 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Peter J. Arduini | CEO, President | 2022 | 1,250,000 | 0 | 61,359,617 | 890,625 | 120,520 | 10,497,102 |
| Helmut Zodl | Chief Financial Officer | 2022 | 750,000 | 0 | 1,483,209 | 491,625 | 97,301 | 2,822,135 |
| Frank R. Jimenez | Corporate Secretary, General Counsel | 2022 | 728,571 | 0 | 51,624,317 | 458,483 | 664,485 | 7,013,970 |
| Betty D. Larson | Chief People Officer | 2022 | 541,667 | 675,000 | 42,289,537 | 290,421 | 272,918 | 6,008,959 |
| Jan Makela | CEO, President | 2022 | 6,185,618 | 0 | 1,853,999 | 3,216,528 | 14,845 | 2,809,057 |
| Fiscal Year | Employee Count |
|---|---|
| 2022 | 50,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 19,672,000,000 | 19,552,000,000 | — |
| Cost Of Revenue | 8,271,000,000 | 8,465,000,000 | — |
| Gross Profit | 8,205,000,000 | 7,922,000,000 | — |
| Research And Development Expenses | 1,311,000,000 | 1,205,000,000 | — |
| General And Administrative Expenses | 4,269,000,000 | 4,282,000,000 | — |
| Operating Expenses | 5,580,000,000 | 5,487,000,000 | — |
| Operating Income | 2,625,000,000 | 2,435,000,000 | — |
| Net Income | 1,993,000,000 | 1,568,000,000 | — |
| Earnings Per Share Basic | 4.37 | 3.05 | — |
| Earnings Per Share Diluted | 4.34 | 3.03 | — |
| Weighted Average Shares Outstanding Basic | 456,000,000 | 455,000,000 | — |
| Weighted Average Shares Outstanding Diluted | 459,000,000 | 458,000,000 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,874,000,000 | 2,494,000,000 | — |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 90,000,000 | 97,000,000 | — |
| Inventories | 1,939,000,000 | 1,960,000,000 | — |
| Non Trade Receivables | 115,000,000 | 97,000,000 | — |
| Other Assets Current | 529,000,000 | 389,000,000 | — |
| Total Assets Current | 9,901,000,000 | 9,410,000,000 | — |
| Marketable Securities Non Current | 373,000,000 | 357,000,000 | — |
| Property Plant And Equipment | — | 2,144,000,000 | — |
| Other Assets Non Current | 1,950,000,000 | 1,881,000,000 | — |
| Total Assets Non Current | 2,550,000,000 | 2,500,000,000 | — |
| Total Assets | 33,089,000,000 | 32,454,000,000 | — |
| Accounts Payable | 3,022,000,000 | 2,947,000,000 | — |
| Deferred Revenue | 1,943,000,000 | 1,918,000,000 | — |
| Short Term Debt | 1,502,000,000 | 1,006,000,000 | — |
| Other Liabilities Current | 20,000,000 | 99,000,000 | — |
| Total Liabilities Current | 9,553,000,000 | 8,981,000,000 | — |
| Long Term Debt | 8,951,000,000 | 9,442,000,000 | — |
| Other Liabilities Non Current | 1,796,000,000 | 1,877,000,000 | — |
| Total Liabilities Non Current | 14,884,000,000 | 16,163,000,000 | — |
| Total Liabilities | 24,437,000,000 | 25,144,000,000 | — |
| Common Stock | 5,000,000 | 5,000,000 | — |
| Retained Earnings | 3,262,000,000 | 1,326,000,000 | — |
| Accumulated Other Comprehensive Income | -1,379,000,000 | -691,000,000 | — |
| Total Shareholders Equity | 8,446,000,000 | 7,133,000,000 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 268,000,000 | 248,000,000 | — |
| Share Based Compensation Expense | 125,000,000 | 114,000,000 | — |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 178,000,000 | 185,000,000 | — |
| Change In Inventories | 81,000,000 | -111,000,000 | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 126,000,000 | -13,000,000 | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 1,955,000,000 | 2,101,000,000 | — |
| Purchases Of Marketable Securities | 40,000,000 | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 401,000,000 | 387,000,000 | — |
| Acquisition Of Business | 313,000,000 | 147,000,000 | — |
| Other Investing Activities | 160,000,000 | 25,000,000 | — |
| Cash From Investing Activities | -914,000,000 | -558,000,000 | — |
| Tax Withholding For Share Based Compensation | 93,000,000 | — | — |
| Payments Of Dividends | 55,000,000 | 41,000,000 | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 1,000,000,000 | 0 | — |
| Other Financing Activities | -34,000,000 | -48,000,000 | — |
| Cash From Financing Activities | -573,000,000 | -478,000,000 | — |
| Change In Cash | 387,000,000 | 1,055,000,000 | — |
| Cash At End Of Period | 2,874,000,000 | 2,494,000,000 | — |
| Income Taxes Paid | 491,000,000 | 474,000,000 | — |
| Interest Paid | 550,000,000 | 570,000,000 | — |
| Fiscal Year | 2024 | 2023 |
|---|---|---|
| Earnings Per Share | 4.37 | 3.05 |
| Price To Earnings Ratio | 17.8902 | 25.3508 |
| Earnings Growth Rate | 43.2787 | — |
| Price Earnings To Growth Ratio | 0.4134 | — |
| Book Value Per Share | 18.9737 | 16.0659 |
| Price To Book Ratio | 4.1204 | 4.8127 |
| Ebitda | 2,752,000,000 | 2,290,000,000 |
| Enterprise Value | 43,229,080,000 | 43,134,600,000 |
| Dividend Yield | 0.0015 | 0.0012 |
| Dividend Payout Ratio | 0.0276 | 0.0261 |
| Debt To Equity Ratio | 1.2376 | 1.4647 |
| Capital Expenditures | — | — |
| Free Cash Flow | — | — |
| Return On Equity | 0.236 | 0.2198 |
| One Year Beta | 0.9277 | 1.0468 |
| Three Year Beta | 0.9817 | 1.0294 |
| Five Year Beta | 0.9817 | 1.0294 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Rott Roland | CEO, Imaging | 2025-09-11 | 3,268 | D | 28,860 |
| Rott Roland | CEO, Imaging | 2025-09-11 | 1,614 | A | 30,474 |
| Rott Roland | CEO, Imaging | 2025-09-11 | 1,352 | D | 29,122 |
| Rott Roland | CEO, Imaging | 2025-09-11 | 3,727 | D | 0 |
| Rott Roland | CEO, Imaging | 2025-09-11 | 3,727 | A | 32,128 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Austin Scott | 2025-08-13 | GA08 | Sale | 2025-03-27 | Spouse | $1,001 - $15,000 |
| Rob Bresnahan | 2025-05-31 | PA08 | Purchase | 2025-05-15 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-04-28 | PA08 | Sale | 2025-04-08 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-03-27 | PA08 | Purchase | 2025-02-25 | — | $1,001 - $15,000 |
| Austin Scott | 2023-01-23 | GA08 | Exchange | 2023-01-04 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Carnegie Investment Counsel | 2025-09-30 | 1,569,139 | 20,894 | 75.1 |
| Darwin Wealth Management, LLC | 2025-09-30 | 18,567 | 247 | 75.17 |
| Lowe Wealth Advisors, LLC | 2025-09-30 | 3,229 | 43 | 75.093 |
| MEYER HANDELMAN CO | 2025-09-30 | 1,856,322 | 24,718 | 75.1 |
| HALBERT HARGROVE GLOBAL ADVISORS, LLC | 2025-09-30 | 526 | 7 | 75.1429 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Mid Cap Fund | CFMCX | 35,119 | 2,589,323.87 | 0.2597 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 1,499 | 106,908.68 | 0.0447 |
| Pacer Funds Trust | 2025-07-31 | Pacer Trendpilot US Large Cap ETF | PTLC | 28,312 | 2,019,211.84 | 0.0605 |
| Pacer Funds Trust | 2025-07-31 | Pacer PE/VC ETF | PEVC | 8 | 570.56 | 0.0262 |
| Pacer Funds Trust | 2025-07-31 | Pacer MSCI World Industry Advantage ETF | GLBL | 12 | 855.84 | 0.0923 |